Cong Li | Biological Sciences | Best Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Cong Li | Biological Sciences | Best Researcher Award

Teacher, Northwest A&F University, China

Dr. Cong Li, Ph.D., is an Associate Professor specializing in 🧬 animal molecular quantitative genetics. He focuses on analyzing the genetic basis of key economic traits in 🐐 dairy goats and developing advanced breeding technologies. A recipient of the Shaanxi “Youth Talent Promotion Program” honor, Dr. Li has led over 15 major projects, including the National Natural Science Foundation and the China Postdoctoral Science Foundation. He has authored 60+ papers πŸ“š, 2 national patents πŸ…, and co-authored 6 books. His accolades include awards from the China Animal Science Forum and the Shaanxi Agricultural Science Promotion program.

 

Publication Profile

Orcid

🌟 Academic Background and Recognition

Dr. Li Cong, Ph.D., is an Associate Professor and a distinguished researcher in 🧬 animal molecular quantitative genetics. He has been honored with the Youth Talent Promotion Program by the Shaanxi Province “University Science and Technology Association.” His research primarily focuses on analyzing the genetic basis of economically significant traits in 🐐 dairy goats and advancing innovative breeding technologies to enhance livestock productivity.

Employment

Assoc. Prof. Dr. Cong Li has been serving as an Associate Professor at the College of Animal Science and Technology, Northwest A&F University, Yangling, China, since July 8, 2016. 🏫 In this role, he has made significant contributions to the field of 🧬 animal molecular quantitative genetics, focusing on genetic analysis and breeding technologies for dairy goats 🐐. His ongoing research has elevated the university’s standing in agricultural and genetic sciences. With his innovative approach and dedication, Dr. Li continues to lead impactful studies that enhance livestock productivity and genetic research methodologies. πŸš€

 

🧬 Research Focus

Assoc. Prof. Dr. Cong Li specializes in animal molecular quantitative genetics, focusing on the genetic basis of economically significant traits in dairy goats 🐐. His work emphasizes milk fatty acid metabolism, protein synthesis, and lipid traits, supported by cutting-edge research in mammary epithelial cells πŸ§ͺ. Dr. Li explores pathways like AKT/PPARG and mTOR signaling, addressing advancements in goat breeding technologies and livestock productivity 🚜. His studies also delve into gene expression, microbial diversity, and the genetic regulation of milk quality traits, benefiting both dairy goats and Holstein cattle πŸ₯›. This impactful research ensures sustainable and high-quality dairy production 🌱.

 

Publication Top NotesΒ πŸ“š

  • TRIB3 suppresses milk fatty acids metabolism by inhibiting p‐AKT/PPARG signaling in goat mammary epithelial cells (2024) 🐐πŸ₯›| DOI: 10.1002/aro2.98
  • Leucine-Mediated SLC7A5 Promotes Milk Protein and Milk Fat Synthesis through mTOR Signaling Pathway in Goat Mammary Epithelial Cells (2024) 🐐πŸ’ͺ | DOI: 10.1021/acs.jafc.4c02087
  • Effect of Algae Supplementation on the Gene Expression of Liver Lipid Metabolism in Dairy Goat Bucks (2024) πŸπŸƒ | Cited by: N/A | DOI: 10.3390/agriculture14050685
  • Genetics and Production of Safe, High-Quality Milk by Dairy Cattle (2023) πŸ„πŸ§€| DOI: 10.3390/agriculture13071348
  • Scd1 Deficiency in Early Embryos Affects Blastocyst ICM Formation through RPs-Mdm2-p53 Pathway (2023) πŸ§¬πŸ‘Ά| DOI: 10.3390/ijms24021750
  • Comparison of microbial diversity in rumen and small intestine of Xinong Saanen dairy goats using 16S rRNA gene high-throughput sequencing (2021) 🦠🐐| DOI: 10.1071/AN20459
  • Identification and characterization of putative ovarian lincRNAs in dairy goats treated for repeated estrous synchronization (2020) πŸπŸ’‰| DOI: 10.1016/j.anireprosci.2020.106537
  • Identification of genetic effects and potential causal polymorphisms of CPM gene impacting milk fatty acid traits in Chinese Holstein (2020) πŸ„| DOI: 10.1111/age.12936
  • Role of peroxisome proliferator-activated receptor-Ξ± on the synthesis of monounsaturated fatty acids in goat mammary epithelial cells (2020) 🐐🧴| DOI: 10.1093/jas/skaa062
  • Association of UDP-galactose-4-epimerase (GALE) with milk protein concentration in the Chinese Holstein population (2020) πŸ„πŸ§€| DOI: 10.5713/ajas.19.0549

Mai O. Kadry | Molecular Biology | Best Researcher Award

Posted on by ScienceFather

Assist. Prof. Dr. Mai O.Kadry | Molecular Biology | Best Researcher Award

Assist. Prof. Dr. Mai O.Kadry,National Research Center, Egypt

Dr. Mai Osman Mohamed Kadry is a distinguished biochemistry researcher at the Therapeutic Chemistry Department, National Research Centre, Egypt. With a Doctorate in Biochemistry from Cairo University (2016), her work focuses on oxidative injury, nanotoxicity, and cancer therapy. She has published extensively in high-impact journals on topics like antioxidant effects, stem cell therapies, and metabolic disorders. Dr. Kadry has also contributed to academia, teaching pharmacognosy at 6th October University. Skilled in advanced techniques like PCR, HPLC, and ELISA, she actively participates in groundbreaking nanobiotechnology research projects. Dr. Kadry is committed to advancing therapeutic strategies for critical diseases. πŸ“šπŸ§¬

Publication Profile

Scopus

Academic and Professional Experience πŸŒŸπŸŽ“

Assist. Prof. Dr. Mai O. Kadry has accumulated valuable experience in academia and research. She served as a pharmacognosy instructor at the Faculty of Pharmacy, 6th October University, Cairo, Egypt (2003–2004), where she effectively delivered courses on natural products and their therapeutic applications. Dr. Kadry also contributed as a staff member focused on development and quality enhancement, aligning with the standards of the National Commission for Academic Accreditation. Her dedication to education and quality assurance reflects her commitment to fostering academic excellence and professional growth in pharmaceutical sciences. πŸ“šπŸ”¬

 

Educational Background πŸŽ“πŸ“˜

Assist. Prof. Dr. Mai O. Kadry boasts a strong academic foundation in pharmaceutical sciences. She earned her Doctorate in Biochemistry from the Faculty of Pharmacy, Cairo University, in 2016, with a thesis on the “Amelioration of Nano-Sized Titanium Dioxide-Induced Oxidative Injury in Mice by Some Antioxidants.” She obtained her Master’s degree in Pharmaceutical Sciences from Helwan University in 2008, focusing on the synergistic effects of phytic and catechin on carbon tetrachloride-induced damage in rats. Dr. Kadry completed her B.Sc. in Pharmaceutical Science at Ain Shams University in 2003, graduating with honors. She also attended English language schools, enhancing her global communication skills. πŸŒŸπŸ”¬

 

Training πŸ§¬πŸ“š

Assist. Prof. Dr. Mai O. Kadry has undergone extensive training in various scientific disciplines. She completed courses in Biostatistics (November 2016) and Bioinformatics (January 2017) at the National Research Centre. Earlier, she gained expertise in Scientific Typewriting Bases (March 2007) and Occupational Health and Safety (June 2009). Additionally, she mastered Protein Electrophoresis through a four-month course in 2006. Dr. Kadry enhanced her practical skills with hands-on training at Al-Borg Clinical Laboratory, focusing on PCR techniques for detecting HBV and HCV at the Theodor Bilharz Research Institute. Her comprehensive training equips her with valuable laboratory and analytical skills. πŸ”¬πŸ§ͺ

 

Research Focus πŸ§ͺ🧠🧬

Assist. Prof. Dr. Mai O. Kadry focuses on cutting-edge biomedical research, emphasizing toxicity, cancer therapy, and molecular biology. Her work explores inflammatory mediators, DNA damage, and therapeutic approaches in liver, brain, and nephrotoxicity contexts. She investigates autophagy, necroptosis, and novel strategies like resveratrol nano-formulations for ovarian cancer. Dr. Kadry also studies molecular pathways in gastric and prostate cancers, including miRNA-lncRNA signaling and CRISPR-Cas9 applications. Other interests involve genetic mutations in leukemia, drug-delivery systems, and nanotechnology for breast cancer. Her contributions bridge diagnostics, therapeutic innovations, and cellular mechanisms in oncology and toxicology. πŸ”¬βœ¨

 

Publication Top Notes

  • Inflammatory mediators-induced DNA damage in liver and brain injury: Therapeutic approach of 5-Methoy-N-acetyltryptamine – 2024, Toxicology Reports 🧬
  • Necroptosis and autophagy in cisplatinum-triggered nephrotoxicity: Novel insights regarding prognostic and diagnostic potential – 2024, Toxicology Reports πŸ§ͺ
  • Resveratrol-based nano-formulations as a therapeutic strategy for ovarian carcinoma: Autophagy and SIRT-1 signaling – 2024, Cancer Nanotechnology πŸ’Š
  • miR-122-IGF-1R signaling allied with dysregulated lncRNA MALAT-1 in gastric carcinoma – 2024, Toxicology Reports πŸ”¬ (Cited by: 1)
  • Reciprocal crosslink among MeCP2/BDNF/CREB signaling in autism spectrum disorder – 2024, Toxicology Reports 🧠
  • CRISPR-Cas9 genome and lncRNAs for prostate cancer therapy via liposomal compounds – 2024, PLoS ONE 🧬 (Cited by: 1)
  • Collaboration of Hprt/K-RAS/c-Myc mutation in T-lymphocytic leukemia oncogenesis – 2024, Future Science OA πŸ§ͺ (Cited by: 1)
  • Thioctic acid shield against lipopolysaccharide depression and endoplasmic stress – 2024, Future Science OA 🧫
  • Titanium dioxide nanostructure-loaded Adriamycin in breast cancer therapy – 2024, Future Science OA πŸŽ—οΈ (Cited by: 1)
  • Alleviation of doxorubicin adverse effects via drug-delivery systems – 2024, Therapeutic Delivery πŸš‘

 

Junfang Zheng | Molecular Biology Award | Best Researcher Award

Posted on by ScienceFather

Dr. Junfang Zheng | Molecular Biology Award | Best Researcher Award

Dr. Junfang Zheng, Capital medical university, China

Based on Dr. Junfang Zheng’s academic background, current and previous appointments, and honors and awards, he appears to be a strong candidate for the Research for Best Researcher Award. Here’s an evaluation of his qualifications:

Publication profile

Scopus

Education:

Dr. Zheng has a solid educational foundation with a B.M. in Traditional Chinese Medicine from Shanxi University of Chinese Medicine, followed by an M.Sc. in Diagnostics of Traditional Chinese Medicine from Beijing University of Chinese Medicine. His Ph.D. in Pathogenic Biology from Peking University further strengthens his expertise, indicating a robust background in both traditional and modern aspects of medical research.

Current Appointment:

Since 2006, Dr. Zheng has been a Professor in the Department of Biochemistry and Molecular Biology at Capital Medical University. This long-term position reflects his established career and significant contributions to his field.

Previous Appointments:

Dr. Zheng’s previous roles include a Visiting Fellow at the Medical University of Vienna and a Postdoctoral Fellow at Tsinghua University. These positions highlight his international experience and commitment to advancing his research in different academic environments.

Honors, Awards, and Grants:

Dr. Zheng has received multiple prestigious awards, including the Guanghua Fellowship from Peking University, the Eurasia Pacific Uninet Scholarship from Austria, and several funds and honors from Beijing and China. These recognitions underscore his high-impact research contributions and the esteem in which he is held within the academic community.

Publication Top Notes Β 

  • YTHDF3 phase separation regulates HSPA13-dependent clear cell renal cell carcinoma development and immune evasion 🧬 β€” Cancer Science, 2024, 0 citations
  • PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway πŸ§ͺ β€” Cell Death and Disease, 2024, 0 citations
  • ARHGAP11A Is a Novel Prognostic and Predictive Biomarker Correlated with Immunosuppressive Microenvironment in Clear Cell Renal Cell Carcinoma πŸ”¬ β€” International Journal of Molecular Sciences, 2023, 2 citations
  • GLUD1 suppresses renal tumorigenesis and development via inhibiting PI3K/Akt/mTOR pathway 🧫 β€” Frontiers in Oncology, 2022, 6 citations
  • Inhibitor tolerance and bioethanol fermentability of levoglucosan-utilizing Escherichia coli were enhanced by overexpression of stress-responsive gene ycfR πŸ”¬ β€” Synthetic and Systems Biotechnology, 2021, 4 citations
  • Bioactive peptide apelin rescues acute kidney injury by protecting the function of renal tubular mitochondria 🧬 β€” Amino Acids, 2021, 11 citations
  • SDHB Suppresses the Tumorigenesis and Development of ccRCC by Inhibiting Glycolysis πŸ§ͺ β€” Frontiers in Oncology, 2021, 28 citations
  • iTRAQ-facilitated proteomic analysis of Bacillus cereus via degradation of malachite green πŸ”¬ β€” Journal of Microbiology, 2021, 2 citations
  • Long noncoding RNA PENG upregulates PDZK1 expression by sponging miR-15b to suppress clear cell renal cell carcinoma cell proliferation 🧬 β€” Oncogene, 2020, 26 citations
  • ECHS1 suppresses renal cell carcinoma development through inhibiting mTOR signaling activation πŸ”¬ β€” Biomedicine and Pharmacotherapy, 2020, 16 citations


Conclusion

Dr. Zheng’s extensive educational background, notable appointments, and numerous awards make him a highly suitable candidate for the Research for Best Researcher Award. His achievements and international experience align well with the criteria for such an award.